Skip to main content

Table 8 Hearing loss 3 months post first fitting compared to baseline: effect estimate for ACEMg vs. placebo, surgeon, electrode length and age from ANCOVA model adjusted by age as a continuous covariate

From: Randomized placebo-controlled clinical trial investigating the effect of antioxidants and a vasodilator on overall safety and residual hearing preservation in cochlear implant patients

Effect

Estimate

Standard error

p value

95% confidence interval

ACEMg - placebo

− 3.14

4.3410215

0.4735

(− 11.90, 5.62)

Surgeon 2 - other surgeons

− 2.65

4.6540781

0.5715

(− 12.05, 6.74)

Flex 24 - Flex 20

33.99

9.8300736

0.0013

(14.15, 53.83)

Flex 28 - Flex 20

35.54

12.7415605

0.0079

(9.82, 61.25)

Flex 28 - Flex 24

1.55

7.5051096

0.8378

(− 13.60, 16.69)

Baseline

− 0.37

0.1935072

0.0605

(− 0.76, 0.02)

Age

0.28

0.1782778

0.1254

(− 0.08; 0.64)